VRDN stock forecast, quote, news & analysis
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease... Show more
Viridian Therapeutics (VRDN) Stock Analysis: Phase 3 Data Sparks Volatility
Key Takeaways
- Viridian Therapeutics' shares plunged over 30% in recent trading sessions following topline results from the Phase 3 REVEAL-1 trial for elegrobart in active thyroid eye disease (TED), despite meeting the primary endpoint.
- The trial showed statistically significant proptosis responder rates for elegrobart, but secondary endpoints and safety data disappointed investors, leading to heightened volatility.
- Analysts adjusted price targets downward post-data but largely maintained Buy ratings, with an average target around $40, suggesting potential upside.
- Veligrotug BLA remains under FDA Priority Review with a PDUFA date of June 30, 2026, representing a key near-term catalyst.
- Strong cash position of approximately $888 million as of late 2025 supports operations through anticipated profitability.
- Pipeline includes additional Phase 3 data for elegrobart in chronic TED expected mid-2026.
Current Market Snapshot
Viridian Therapeutics (VRDN) stock has experienced significant turbulence in recent weeks amid pivotal clinical updates in its thyroid eye disease (TED) portfolio. Shares faced sharp declines following the release of Phase 3 topline data for subcutaneous candidate elegrobart, reflecting investor reactions to efficacy and safety metrics that fell short of lofty expectations despite hitting primary goals. Trading volume surged dramatically, underscoring intense market interest. Broader sentiment remains tied to the company's advancing pipeline, including the ongoing FDA review of intravenous asset veligrotug. While near-term pressures persist, VRDN's robust cash reserves and multiple catalysts position it as a high-conviction name in the biotech space for patient investors navigating volatility.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform's most promising AI trading bots, drawn from hundreds of sophisticated agents that analyze and trade thousands of tickers across diverse market conditions. These bots employ varied strategies—from pattern recognition and momentum plays to mean reversion and sector rotation—spanning short-term scalps to longer-term swings, with performance metrics like annualized returns often exceeding 100% in top performers, win rates up to 90%, and profit factors above 3.0 in recent evaluations. Only those demonstrating superior risk-adjusted returns, consistency, and adaptability to current volatility earn a spot in this elite lineup. For investors eyeing VRDN's biotech swings or broader opportunities, exploring Trending AI Robots offers data-driven insights to enhance decision-making.
Recent Developments Driving VRDN Price Action
Viridian Therapeutics, a clinical-stage biopharmaceutical company developing therapies for thyroid eye disease (TED)—an autoimmune condition causing eye bulging (proptosis), double vision (diplopia), and inflammation—has seen its stock whipsaw amid key pipeline milestones over the past 30 days. The dominant event was the March 30, 2026, announcement of positive topline results from the Phase 3 REVEAL-1 trial of subcutaneous elegrobart (VRDN-003), an IGF-1R (insulin-like growth factor-1 receptor) inhibitor designed for at-home autoinjector use every four or eight weeks.
REVEAL-1, involving 132 patients with active TED, met its primary endpoint of proptosis responder rate (PRR)—a ≥2 mm reduction in proptosis in the study eye—for both every-four-week (Q4W) and every-eight-week (Q8W) regimens versus placebo, with highly statistically significant p-values. Clinically meaningful improvements in diplopia were also observed, and the safety profile was generally favorable, though low rates of tinnitus-related hearing events emerged. Initial market reaction was positive, with shares jumping intraday, but enthusiasm faded as details revealed metrics lagging benchmarks like Tepezza (teprotumumab), the incumbent intravenous (IV) TED therapy from Horizon Therapeutics. Investors questioned elegrobart's competitive edge in efficacy depth and durability, triggering a over-30% plunge to around $18.50, on record volume exceeding 13 million shares—far above the average 1.4 million.
Analyst responses were swift: Jefferies cut its target from $45 to $29, Needham from $42 to $32, and Wedbush from $44 to $37, citing "lackluster" secondaries and comparisons to IV standards, though most retained Buy ratings. H.C. Wainwright noted the data "falls short of IV benchmark." Consensus remains bullish, with an average target near $40, reflecting belief in elegrobart's convenience as a potential first subcutaneous TED option and upcoming REVEAL-2 data in chronic TED.
Earlier in the period, February 26, 2026, financials highlighted a cash hoard of ~$888 million post-2025 financings ($289 million equity, $170 million DRI royalty), funding through profitability. Q4 2025 EPS was -$1.08 (missed estimates), but operational progress included veligrotug BLA Priority Review (PDUFA June 30, 2026). No major macroeconomic or industry shocks directly impacted VRDN, though biotech sector rotation amplified the data reaction. Inducement grants (January 8) were routine. Overall, price action reflects classic biotech binary risk: trial success tempered by execution hurdles, sentiment shifts, and high expectations in a ~$2 billion TED market.
2026 Outlook and Key Factors to Monitor
As Viridian Therapeutics advances into 2026, focus sharpens on regulatory and clinical milestones shaping its TED franchise. The PDUFA date for veligrotug's BLA on June 30 offers potential U.S. approval and mid-year launch, if granted, as an improved IV IGF-1R option with faster onset and fewer infusions versus Tepezza. EMA filing follows in Q1. REVEAL-2 topline for elegrobart in chronic TED (Q2) will test broader utility, alongside detailed REVEAL-1 disclosures. Investors should track safety signals like hearing events, manufacturing scale-up, and payer dynamics in the competitive TED landscape.
Pipeline expansion includes VRDN-008 (FcRn inhibitor) healthy volunteer data (2H) and TSHR (thyroid-stimulating hormone receptor) inhibitor IND (Q4) for TED/Graves, tapping upstream disease drivers. Cash runway (~$888 million) mitigates dilution risks, but burn from commercialization looms. Macro factors like biotech funding, inflation impacts on trials, and regulatory scrutiny (e.g., diversity plans) warrant attention. Competitive positioning against Tepezza generics and emerging therapies will influence market share potential in a growing TED opportunity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
VRDN in +4.41% Uptrend, rising for three consecutive days on June 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where VRDN advanced for three days, in of 253 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for VRDN crossed bullishly above the 50-day moving average on June 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for VRDN moved out of overbought territory on May 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VRDN as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for VRDN turned negative on June 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
VRDN moved below its 50-day moving average on June 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRDN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
VRDN broke above its upper Bollinger Band on May 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.455) is normal, around the industry mean (18.049). P/E Ratio (0.000) is within average values for comparable stocks, (35.837). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.672). VRDN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (20.000) is also within normal values, averaging (355.556).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. VRDN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRDN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceuticals
Industry Biotechnology